Enlivex (ENLV) Current Assets (2013 - 2025)
Enlivex (ENLV) posted quarterly Current Assets of $1.7 billion for Q4 2025, up 6606.34% year-over-year from $26.0 million in Q4 2024, and up 8840.29% quarter-over-quarter from $19.5 million in Q3 2025.
Enlivex (ENLV) Current Assets (2013 - 2025) Analysis & Trends
Enlivex's Current Assets history runs 13 years deep, the most recent figure standing at $1.7 billion for Q4 2025.
- In Q4 2025, Current Assets rose 6606.34% year-over-year to $1.7 billion; the TTM figure through Dec 2025 stood at $1.7 billion (up 6606.34% YoY), while the FY2025 annual figure was $1.7 billion, up 6606.34% from the prior year.
- Current Assets for Q4 2025 stood at $1.7 billion, up from $19.5 million in the prior quarter.
- The five-year high for Current Assets was $1.7 billion in Q4 2025, with the low at $19.5 million in Q3 2025.
- The 5-year median for Current Assets is $35.7 million (2023), against an average of $133.5 million.
- The sharpest annual moves came in 2023 and 2025: Current Assets sank 52.68% in 2023, then soared 6606.34% in 2025.
- Enlivex's Current Assets stood at $86.4 million in 2021, then sank by 39.46% to $52.3 million in 2022, then tumbled by 35.48% to $33.8 million in 2023, then retreated by 23.02% to $26.0 million in 2024, then jumped by 6606.34% to $1.7 billion in 2025.
- Business Quant data shows ENLV's Current Assets at $1.7 billion in Q4 2025, $19.5 million in Q3 2025, and $21.3 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.62 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.63 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 1.76 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 18.80 Bn |
| 10 | Enlivex | 4.58 Mn | -1.17 Mn | - | 1.74 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.74 Bn |
| Sep 30, 2025 | 19.50 Mn |
| Jun 30, 2025 | 21.32 Mn |
| Mar 31, 2025 | 22.65 Mn |
| Dec 31, 2024 | 25.99 Mn |
| Sep 30, 2024 | 27.11 Mn |
| Jun 30, 2024 | 28.57 Mn |
| Mar 31, 2024 | 28.38 Mn |
| Dec 31, 2023 | 33.76 Mn |
| Sep 30, 2023 | 31.84 Mn |
| Jun 30, 2023 | 30.79 Mn |
| Mar 31, 2023 | 37.58 Mn |
| Dec 31, 2022 | 52.33 Mn |
| Sep 30, 2022 | 59.23 Mn |
| Jun 30, 2022 | 65.05 Mn |
| Mar 31, 2022 | 79.30 Mn |
| Dec 31, 2021 | 86.44 Mn |
| Sep 30, 2021 | 90.28 Mn |
| Jun 30, 2021 | 92.83 Mn |
| Mar 31, 2021 | 93.78 Mn |